P4-BETA: Impact of Serum Progesterone Levels on the Day of β-hCG Test in Artificial Cycles on the Ongoing Pregnancy Rate.

Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA (Other)
Overall Status
Recruiting
CT.gov ID
NCT05750849
Collaborator
(none)
900
1
22.2
40.5

Study Details

Study Description

Brief Summary

Prospective cohort multicentric study including infertile patients undergoing a pregnancy test on βhCG day (around ET +11), after an ET in the context of an artificial cycle and receiving LPS with vaginal natural progesterone following the clinical practice in IVI RMA (Spain).

Condition or Disease Intervention/Treatment Phase
  • Procedure: BLOOD COLLECTION FOR P4 DETERMINATION

Detailed Description

The investigation team have already demonstrated that serum progesterone levels measured on the ET day in artificial cycles are related to pregnancy outcome. In this line, this problem can be countteracted after supplementation with an additional source of external progesterone, achieving similar ongoing pregnancy and live birth rates in women with serum progesterone levels below and above the threshold point determined on the ET day.

Despite this, it has been observed apparent differences on the maintenance of pregnancy in patients with a positive pregnancy test according to their serum progesterone levels measured on day ET+11, which is the same day in which we perform the pregnancy test. These differences seem to be originated due to later higher clinical miscarriage rates in patients with lower serum progesterone levels on day ET+11, despite their positive pregnancy test.

This fact may be due to patientes low serum progesterone levels, insufficient to maintain an ongoing pregnancy. Taking this into account, this study aim to confirm that serum progesterone levels on βhCG day are indeed related to final pregnancy outcome and to evaluate if there is any cut-off point of serum progesterone levels, as we have previously found on the ET day.

Study Design

Study Type:
Observational
Anticipated Enrollment :
900 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Serum Progesterone Levels on the Day of β-hCG Test in Artificial Cycles on the Ongoing Pregnancy Rate.
Actual Study Start Date :
Jan 25, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
OPTIMAL SERUM P4 LEVEL

Serum progesterone levels on β-hCG day over the threshold point calculated

Procedure: BLOOD COLLECTION FOR P4 DETERMINATION
Serum progesterone levels on the pregnancy test day

SUB-OPTIMAL SERUM P4 LEVEL

Serum progesterone levels on β-hCG day below the threshold point calculated

Procedure: BLOOD COLLECTION FOR P4 DETERMINATION
Serum progesterone levels on the pregnancy test day

Outcome Measures

Primary Outcome Measures

  1. LIVE BIRTH [1 YEAR]

    Record of live birth existence

  2. ONGOING PREGNANCY [1 YEAR]

    Pregnancy confirmation by the observation of the presence of at least one gestational sac on ultrasound

  3. POSITIVE PREGANCY [1 YEAR]

    Measurement of pregnancy test results

  4. BIOCHEMICAL MISCARRIAGE [1 YEAR]

    Measurement of existence of miscarriage after a positive pregnancy test

  5. CLINICAL MISCARRIAGE [1 YEAR]

    Measurement of existence of Miscarriage after confirmation of at least one gestational sac on ultrasound

Secondary Outcome Measures

  1. SERUM P4 LEVEL ON B-HCG DAY [1 YEAR]

    Measurement of serum progesterone levels on the pregnancy test day

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The subject must provide written informed consent prior to any study related procedures

  • Women ≤50 years old

  • BMI ≤ 35 kg/m2

  • Adequate endometrial thickness (>6.5mm) and pattern (Triple A structure) in the proliferative phase

Exclusion Criteria:
  • Uterine Pathology, adnexal pathology

  • Systemic diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 IVI RMA Valencia Valencia Spain 46015

Sponsors and Collaborators

  • Instituto Valenciano de Infertilidad, IVI VALENCIA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Instituto Valenciano de Infertilidad, IVI VALENCIA
ClinicalTrials.gov Identifier:
NCT05750849
Other Study ID Numbers:
  • 2209-VLC-135-EL
First Posted:
Mar 2, 2023
Last Update Posted:
Mar 3, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2023